Shots:

• Boehringer Ingelheim acquires ICD Therapeutics in all stock transaction- to utilize ICD’s MacroDel biologics-delivery platform to develop oncology therapies for intracellular delivery of macromolecules (peptides and proteins)
• The focus of the acquisition is to enhance Boehringer’s oncology portfolio with the development of therapies for intracellular targets for tumor cell types
• ICD’s MacroDel technology is a novel biologics-delivery platform targeting transporter proteins in the cell membrane to deliver therapies intracellularly. Additionally- BI will collaborate with nanoPET Pharma (former share holder of ICD Therapeutics) to develop therapies with ICD’s platform

Ref: Boehringer Ingelheim | Image: Missouri Business Alert